Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition-Reference-Cited by-同舟云学术

Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition

Published:2022-03-07 Issue:4 Volume:42 Page:360-364
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Schneeweis Christian¹,Hassan Zonera¹,Ascherl Katja¹,Wirth Matthias²^ORCID,Koutsouli Stella³,Orben Felix¹^ORCID,Krauß Lukas¹^ORCID,Schneider Carolin¹,Öllinger Rupert⁴,Krämer Oliver H.⁵,Rad Roland⁴⁶,Reichert Maximilian¹⁶⁷,Robles Maria S.³,Saur Dieter⁶⁸,Schneider Günter¹⁹^ORCID

Affiliation:

1. Medical Clinic and Polyclinic II Klinikum rechts der Isar Technical University Munich Munich 81675 Germany

2. Department of Hematology Oncology and Tumor Immunology Charité ‐ Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin 12203 Germany

3. Institute of Medical Psychology and Biomedical Center (BMC) Faculty of Medicine LMU Munich Munich 80336 Germany

4. Institute of Molecular Oncology and Functional Genomics TUM School of Medicine Technical University Munich Munich 81675 Germany

5. Department of Toxicology University of Mainz Medical Center Mainz 55131 Germany

6. German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) Heidelberg 69120 Germany

7. Center for Protein Assemblies (CPA) Technical University of Munich Garching 85747 Germany

8. Institute for Translational Cancer Research and Experimental Cancer Therapy Technical University Munich Munich 81675 Germany

9. Department of General Visceral and Pediatric Surgery University Medical Center Göttingen Göttingen 37075 Germany

Funder

Deutsche Krebshilfe

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12280

Reference10 articles.

1. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting

2. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine

3. MTOR inhibitor-based combination therapies for pancreatic cancer

4. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer

5. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mychonastes sp. 246 Suppresses Human Pancreatic Cancer Cell Growth via IGFBP3-PI3K-mTOR Signaling;Journal of Microbiology and Biotechnology;2022-12-12